| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8624130 | Experimental and Molecular Pathology | 2018 | 28 Pages |
Abstract
Our results suggest that the function of CD10 may change during tumour evolution. It may inhibit cell motility in early-stage disease whilst promoting cell viability in late-stage disease. It has a complex role and further studies are needed to elucidate the suitability of CD10 as a prognostic marker or therapeutic target.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Clinical Biochemistry
Authors
Teresa P. Raposo, Mireia Sueca Comes, Adeyemi Idowu, Bora Agit, James Hassall, Wakkas Fadhil, Robert Nica, Rupert Ecker, Takashi Yao, Mohammad Ilyas,